|Bid||0.0000 x 900|
|Ask||0.0000 x 1100|
|Day's Range||2.0000 - 2.1900|
|52 Week Range||1.5600 - 6.3200|
|Beta (3Y Monthly)||3.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nasdaq: GENE, “Company”), a diversified molecular diagnostics company, today announced that it has entered into a securities purchase agreement with certain accredited institutional investors, pursuant to which the investors have agreed to purchase an aggregate of 1,476,143 American Depositary Shares (“ADSs”), each representing one hundred and fifty (150) of the Company’s ordinary shares, at a price of $0.80 per ADS. The Company will receive gross proceeds of approximately USD 1.2 million, before deducting customary offering expenses. The investors also agreed to purchase warrants to purchase an aggregate of 1,107,107 ADSs at an exercise price of $0.80 per share (the “Warrants”). The warrants will be exercisable immediately following the date of issuance, will expire on the five year anniversary of the date of issuance.
MELBOURNE, Australia, May 17, 2019 -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce an interview with its Chairman.
NASDAQ Ticker: GENE) is delighted to announce that following substantial scientific research and genetic product development, two new ground-breaking cancer risk assessment tests have now been completed and validated. The new tests for colorectal cancer and breast cancer are world-leading. GTG’s polygenic risk tests combine information from genetic markers called Single Nucleotide Polymorphisms to assess how people’s genetic make-up affects their risk of developing various diseases.
MELBOURNE, Australia, May 03, 2019 -- Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) announces that it has received a letter from the.
Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”), a provider of world-leading genetic risk assessment test products, is pleased to announce that it has now established a Memorandum of Understanding (MoU) with The Translational Genomics Research Institute (TGen). TGen is an Arizona-based, non-profit biomedical research institute dedicated to conducting ground-breaking research with life-changing results. TGen works to unravel the genetic components of common and complex diseases, including cancer, neurological disorders, infectious disease, and rare childhood disorders.
Highlights Genetic Technologies establishes Asian operations in China.The move into Asia includes the formation of Genetic Technologies HK Limited and Hainan Aocheng Genetic.
MELBOURNE, Australia, Feb. 01, 2019 -- Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE, “Company”), a diversified molecular diagnostics company is pleased to announce the.
Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, provides today an update on its R&D program for the year. As announced to the market on 16th March 2018, Genetic Technologies Limited has embarked on a collaborative research program with academic research staff from the Centre for Epidemiology and Biostatistics at The University of Melbourne. Led by Professor John Hopper, the research is designed to broaden the applicability of the BREVAGenplus® breast cancer risk assessment test enabling its use in women with an extended family history of disease and will also increase the range of risk factors analysed.
MELBOURNE, Australia, Dec. 20, 2018 -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), via its subsidiary Gene Ventures Pty Ltd, is pleased to announce that.